Spire Wealth Management Catalyst Pharmaceuticals, Inc. Transaction History
Spire Wealth Management
- $2.7 Billion
- Q2 2025
A detailed history of Spire Wealth Management transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Spire Wealth Management holds 14,100 shares of CPRX stock, worth $280,026. This represents 0.01% of its overall portfolio holdings.
Number of Shares
14,100
Previous 18,429
23.49%
Holding current value
$280,026
Previous $446,000
31.61%
% of portfolio
0.01%
Previous 0.01%
Shares
5 transactions
Others Institutions Holding CPRX
# of Institutions
389Shares Held
100MCall Options Held
37KPut Options Held
20.5K-
Black Rock Inc. New York, NY18.7MShares$371 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.5MShares$169 Million0.0% of portfolio
-
State Street Corp Boston, MA5.53MShares$110 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.42MShares$68 Million2.1% of portfolio
-
Goldman Sachs Group Inc New York, NY3.14MShares$62.3 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.04B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...